News

Dr. Milan Crnogorac joins RocketVax AG as Chief Technology Officer

9 August 2022

Bilanz: Important Milestone

28 June 2022

Finanz und Wirtschaft: Doubts about the market for corona boosters

24 June 2022

RocketVax SARS-CoV-2 Vaccine (RVX-sCPD9) Significantly Outperforms mRNA and Adenovirus Vector-Based Technologies in Animal Models

9 June 2022

RocketVax strengthens its technology portfolio and Covid-19 vaccine development through broad-based partnerships

16 March 2022

Dr. Vladimir Cmiljanovic is the recipient of the 2021 Nikola Tesla Award for the achievements in the field of science

12 November 2021

Swiss biotech companies in fight against the coronavirus

18 April 2022

Volker Thiel: “There can be a summer wave”

28 March 2022

Swiss vaccine candidates enter clinical trial phase

28 March 2022

New Swiss COVID-19 vaccination as a nasal spray

28 March 2022

Serbian state institutions and media representatives have been reporting on the recipient of the Nikola Tesla Award, Dr. Vladimir Cmiljanovic

18 November 2021

CEO of RocketVax, Dr. Vladimir Cmiljanovic, spoke to RTS about the development of a second-generation SARS-CoV-2 vaccine

30 September 2021

L’Avenir: “Two new vaccines are expected in late 2021”

19 August 2021

Le Temps is reporting about CHF 7.2 million of seed funding raised for the development of RocketVax’s SARS-CoV-2 vaccine

6 August 2021

RocketVax successfully raises CHF 7.2 million of seed funding

3 August 2021